


Interim Report

MeVis Medical Solutions AG H1-2021/2022



MeVis

CONTENT

LETTER FROM THE CEO	2
THE MEVIS SHARE	4
INTERIM MANAGEMENT REPORT H1 2021/2022.....	5
Preamble	5
Basics of the Company	5
Structure	5
Short summary of the business activities	5
Economic report.....	6
Business development	6
Earnings position	6
Net assets and financial position.....	7
Opportunities and risk report.....	7
Outlook	8
BALANCE SHEET	9
PROFIT AND LOSS ACCOUNT	11
NOTES TO THE FINANCIAL STATEMENTS.....	12
Basic information	12
General information	12
Accounting and valuation methods	12
Selected notes on the balance sheet and income statement.....	13
1. Receivables and other assets.....	13
2. Accruals/Provisions	13
3. Liabilities.....	13
4. Deferred income	13
5. Revenues	13
6. Other operating income	14
7. Staff costs.....	14
8. Other operating expenses	14
9. Relationships with related parties	14
Material events occurring after the balance sheet date.....	14
ASSURANCE OF THE LEGAL REPRESENTATIVE	15
DISCLAIMER	16

LETTER FROM THE CEO

Dear Readers,

In the first half of the 2021/2022 financial year, the Company's revenues amounted to € 8,546 k (prev. year: € 8,080 k). The sale of licenses accounted for 26 % (prev. year: 30 %) of revenues, maintenance revenues for 30 % (prev. year: 35 %), and other revenues for 44 % (prev. year: 35 %), which include, among other things, services provided to and recharges made to affiliated companies and the parent company. Earnings before interest and taxes (EBIT) increased from € 2,378 k to € 3,378 k, mainly as a result of higher sales and lower other operating expenses compared with the previous year, corresponding to an attractive EBIT margin of 40 %.

The change in our MeVis business structure continues. License sales are slightly down compared to the previous year, as are maintenance sales. The slight decline in licensing business is caused by the fact that projects in the field of lung diagnostics were postponed and that license sales of our MeVisLab development platform declined slightly. The slight decrease in maintenance revenues is due to the Digital Mammography business. In contrast, other sales have gained strongly in importance for MeVis compared to previous years. In particular, development services have developed better than expected in the last 6 months, mainly in projects with Varian Medical Systems and also Hologic.

As in the previous year, new business with our lung cancer screening products unfortunately fell short of our expectations. The positive demand for the products has not changed, but unfortunately installations of the software have been partly postponed, which is also due to the fact that computer hardware was not available due to the global supply situation for computer components. The general positive trend in Europe towards the adoption of lung CT screening is still clearly visible, but has been delayed due to the Corona pandemic. We hope that the trend will pick up and continue to have a positive impact on the marketing of our lung cancer screening products in the future.

In the middle of the first half of the year, we began actively marketing a new software application in the field of liver diagnostics and surgery in Europe. Initial sales and feedback at congresses and trade shows make us very positive about the future success of the application.

We continue to be affected by the Corona pandemic and its aftermath. Although the global economy has meanwhile recovered somewhat from the crisis, its effects continue to shape economic development. At present, supply shortages and low transport capacities are still having a negative impact on the positive trend. We therefore still cannot rule out the possibility of a negative impact on our sales performance in the further course of the financial year, e.g. as a result of a drop in demand from industrial customers, hospitals and clinics due to a shift in priorities for new investments. Furthermore, payment difficulties on the part of customers could lead to liquidity shortfalls.

Even though many Corona measures are slowly being phased out and things are gradually moving towards normality, the crisis team set up in 2020 under the leadership of the Executive Board continued to monitor the situation continuously and prudently in the first half of financial year 2021/2022 and steered measures to safeguard business operations, such as increased hygiene and safety standards. Although we once again had to hold our Annual General Meeting as a virtual meeting without the physical presence of shareholders and their proxies, trade shows and events are increasingly taking place again and visits to customers and travel activities have increased significantly since the start of the new financial year. Working from home (home office), which continues to be used by parts of the workforce, is functioning smoothly for the most part, also due to the use of video conferencing and largely digitalized business processes. We have not yet identified any significant impact of the Covid 19 pandemic on our business operations.

Since the end of February 2022, we are also concerned with the Ukraine-Russia conflict, i.e. the illegal crossing of the borders of the Ukrainian territory by the Russian military and the subsequently introduced extensive sanctions of the Western community of values against the aggressor Russia and partly against Belarus. From today's perspective, the impact of the Russian attack on Ukraine and the sanctions on the global economy and the

development of many companies can hardly be estimated. In particular, the increased energy prices as a result of the dependence on Russian raw materials and the associated additional costs, the possible lack of gas supplies and also the lack of suppliers are causing great concern. The Executive Board of MeVis Medical Solutions AG supports the restrictive measures initiated against Russia and regularly monitors compliance with all sanctions. The medical technology segment is not currently subject to sanctions and at this point in time we are only assuming higher energy prices for the Company and anticipate price increases and delays in purchasing/procurement and logistics similar to the effects of the Corona pandemic.

At this point in time, we are therefore confirming our forecast: For the financial year 2021/2022, revenues are now expected to remain stable compared with the previous year at between € 16.0 million and € 16.5 million. In addition to the slight decline in sales with the customer Hologic, slightly increasing sales revenues are expected in the area of development services. For earnings before interest and taxes (EBIT), we also expect stability in the range of € 4.0 million to € 4.5 million. The forecast sales stability, with an expected balanced result from exchange rate differences, is the main driver for the unchanged outlook for EBIT.

As in the past reporting period, the Executive Board will regularly review its expectations in the course of financial year 2021/2022 on the basis of current business performance.

A handwritten signature in black ink, appearing to read 'Marcus Kirchhoff', with a stylized flourish at the end.

Marcus Kirchhoff
CEO

THE MEVIS SHARE

STATUS 31.03.2022	
ISIN / WKN / Ticker Symbol	DE000A0LBFE4 / A0LBFE / M3V
Industry sector	Software / Medical Technology
Subscribed capital	€ 1,820,000.00
No. of shares	1,820,000
Last quotation (XETRA) on September 30, 2021	€ 32.60
Last quotation (XETRA) on March 31, 2022	€ 33.40
Period high/low (XETRA) in 2021/2022	€ 36.00 / € 30.00
Market capitalization	€ 60,788 Mio.
General Standard (regulated market)	Frankfurt und Xetra
Over-the-counter markets	Berlin, Duesseldorf, Munich, Stuttgart
Indices	CDAX, General All-Share, DAXsector All Software

SHARE PRICE DEVELOPMENT

The share price of MeVis Medical Solutions AG remained stable from October 1, 2021 to March 31, 2022 at an average level of € 32.00. At the beginning of the fiscal year, the share was quoted at € 32.60 and closed at the end of March at € 33.40 in Xetra trading. In the course of the first half of fiscal year 2021/2022, the share reached a high of € 36.00 and a low of € 30.00 in Xetra trading. Compared to € 32.40 at the end of March 31, 2021, the value of the MeVis share increased by 3% in twelve months. As of March 31, 2022, the market capitalization, taking into account 1,820,000 shares outstanding, thus amounted to approx. € 61 million.

SHAREHOLDER STRUCTURE AS AT MARCH 31, 2022

As of the balance sheet date, 73.66 % of the total share capital of MeVis Medical Solutions AG was held by Varex Imaging Deutschland AG, an indirect subsidiary of Varex Imaging Corporation, Salt Lake City, Utah, USA. Another institutional shareholder is HANSAINVEST Hanseatische Investment-GmbH with approx. 12.57 % of the total share capital of MeVis Medical Solutions AG according to the shareholder notifications we received. This means that around 13.78 % of the shares are currently in free float.

COMPENSATION PAYMENT

The domination and profit and loss transfer agreement between Varex Imaging Deutschland AG and MMS AG obliges Varex Imaging Deutschland AG to pay a recurring cash payment ("compensation payment") to the outside shareholders for each full financial year for the duration of this agreement. This amounts to € 1.13 (gross) or € 0.95 (net) per share for each full financial year.

INTERIM MANAGEMENT REPORT H1 2021/2022

PREAMBLE

This report covers the first half of the 2021/2022 financial year, i.e. the period under review from October 1, 2021 to March 31, 2022. The prior-year figures given below refer to the first half of the 2020/2021 financial year from October 1, 2020 to March 31, 2021. MeVis Medical Solutions AG has prepared its annual financial statements for the 2020/2021 financial year in accordance with the provisions of the German Commercial Code applicable to corporations as well as in compliance with the German Stock Corporation Act. This interim financial statements have also been prepared on this basis.

BASICS OF THE COMPANY

STRUCTURE

MeVis Medical Solutions AG (hereinafter also referred to as "MMS AG", "MeVis" or the "Company") was founded in 1997 and commenced business in 1998. 73.66 % of the share capital of MMS AG is currently held by Varex Imaging Deutschland AG, Willich. There is a domination and profit and loss transfer agreement in place between Varex Imaging Deutschland AG, as the controlling company, and MeVis Medical Solutions AG, as the controlled company. Therefore MMS AG is part of the Varex Group through Varex Imaging Deutschland AG under the management of Varex Imaging Corporation, Salt Lake City, Utah, USA.

Varex Imaging Corporation prepares the consolidated financial statements for the largest and smallest group of entities and MMS AG is included in these. The consolidated financial statements are filed with the U.S. Securities and Exchange Commission (SEC) and can be obtained from the head office of the group parent company.

Through a joint venture with Siemens Healthcare GmbH, Munich (hereafter: "Siemens"), MMS AG holds 51 % of MeVis BreastCare GmbH & Co. KG, Bremen, (hereafter: "MBC" or "MBC KG").

SHORT SUMMARY OF THE BUSINESS ACTIVITIES

MMS AG develops innovative software for analyzing and evaluating image data and sells it to equipment manufacturers of medical devices and providers of medical IT platforms.

Clinical focuses are image-based early detection and diagnosis of epidemiologically important diseases such as breast, lung, liver and neurological disorders. The software applications support many of the imaging modalities available. These not only include X-ray modalities such as computed tomography, digital mammography or digital tomosynthesis, but also magnetic resonance imaging, digital sonography and the simultaneous use of multiple modalities (multimodality). MeVis supplies technologies and software applications for global medical industry leaders, meeting their needs and helping them to strengthen their technological leadership positions.

In addition to the sale of software licenses and related maintenance contracts, MeVis offers services in the field of software programming for medical technology companies (development services). These comprise the provision of software development teams, i.e. software developers, product and project managers, application specialists and test engineers. The teams support external customers in the development of software modules or applications and in the integration of new functions and new technologies, such as algorithms based on artificial intelligence. Likewise, services are provided to clinical end customers. These include three-dimensional technical visualizations ("MeVis Distant Services"), interactive online training to improve the diagnostic skills of clinicians and internet-based special applications in teleradiology ("MeVis Online Services").

Whereas in the early years of MeVis the focus was on image-based early detection and diagnosis of breast cancer, today MeVis uses its clinical expertise, know-how from the field of breast cancer, innovative technologies as well as its partner network to successively further develop its software solutions for use in other oncological diseases.

ECONOMIC REPORT

BUSINESS DEVELOPMENT

The Company's operating activities consist of the development and sale of software licenses, the associated maintenance business, software programming for medical technology companies (development services) and the provision of services for technical visualizations (distant services) as well as online training.

With around 89 % (prev. year: 90 %) of total sales, the software business, which includes products for the medical technology companies Hologic, Vital Images and Invivo, again accounted for the majority of the Company's total sales in this reporting period.

The first half of the 2021/2022 financial year was again successful for MeVis in terms of its key financial indicators. The Company continued to benefit from Hologic's very good market position in breast cancer screening.

EARNINGS POSITION

In the first half-year, the Company's revenues amounted to € 8,546 k (prev. year: € 8,080 k). 26 % (prev. year: 30 %) of the revenues are attributable to the sale of licenses, 30 % (prev. year: 35 %) to maintenance revenues and 44 % (prev. year: 35 %) to other revenues, which include, among other things, services for and oncharges to affiliated companies and the parent company. The year-on-year decrease in license revenue is mainly due to a reduction in licenses sold to the customer Invivo. The slight decrease in maintenance revenue is mainly due to a decrease in maintenance revenue from the customer Hologic due to a decrease in new maintenance contracts. The year-on-year improvement in other revenue is due to an increase in revenue from development services.

Other operating income amounted to € 1,031 k in the first half-year (prev. year € 781 k). This is mainly composed of income from exchange rate differences amounting to € 955 k (prev. year: € 660 k).

The cost of materials increased to € 194 k (prev. year: € 98 k) because, in contrast to the previous year, external services were used in the lung product area (prev. year: € 74 k). The company's staff costs amounted to € 4,369 k in the first half year (prev. year: € 4,351 k). In the year under review, the average number of permanent employees of the company stayed the same with 104.

Other operating expenses amounted to € 1,586 k in the reporting period (prev. year: € 1,970 k). They comprise expenses from exchange rate differences of € 629 k (prev. year: € 724 k), rental expenses of € 238 k (prev. year: € 267 k), expenses for legal, consulting and auditing services of € 216 k (prev. year: € 443 k), sales expenses of € 63 k (prev. year: € 21 k), operating expenses of € 56 k (prev. year: € 54 k) and other operating expenses of € 384 k (prev. year: € 460 k).

Earnings before interest and taxes (EBIT) increased from € 2,378 k to € 3,378 k, mainly as a result of higher sales and lower other operating expenses compared with the previous year.

Income from loans of financial assets amounted to € 85 k (prev. year: € 80 k) and relates to interest income from the loan granted to Varex Imaging Deutschland AG. This results in earnings before taxes (EBT) of € 3,463 k (prev. year: € 2,458 k).

In the past half-year, income taxes of € 42 k (prev. year: € 42 k) were incurred. Therefore, taking into account the expense from the profit to be transferred to Varex Imaging Deutschland AG of € 3,421 k (prev. year: € 2,416 k), the net profit for the year amounts to € 0 k (prev. year: € 0 k). It should be noted that the expense from the profit and loss transfer does not legally arise until the end of the financial year.

NET ASSETS AND FINANCIAL POSITION

The balance sheet total decreased to € 25,513 k (Sept. 30, 2021: € 27,534 k). In terms of assets, current assets increased by € 1,293 k and the cash and cash equivalents decreased by € 3,312 k. Equity remained constant. Accruals decreased by € 560 k and liabilities decreased by € 1,296 k. Deferred income decreased by € 1,306 k.

The equity ratio increased to 70 % (Sept. 30, 2021: 65 %) due to the lower balance sheet total and the constant equity, while the gearing ratio fell accordingly to 30 % (Sept. 30, 2021: 35 %).

Current assets increased by € 1,293 k to € 4,446 k as of the balance sheet date (Sept. 30, 2021: € 3,153 k). This is mainly due to the increase in trade receivables, which increased by € 1,115 k.

The Company's equity remained constant at € 17,826 k (Sept. 30, 2021: € 17,826 k) and, in addition to the subscribed capital of € 1,820 k (Sept. 30, 2021: € 1,820 k), consists of the capital reserve of € 11.461 k (Sept. 30, 2021: € 11,461 k) as well as the statutory revenue reserves of € 5 k (Sept. 30, 2021: € 5 k) and the other revenue reserves of € 4,540 k (Sept. 30, 2021: € 4,540 k).

Compared to the previous year, provisions decreased by € 560 k to € 2,454 k (Sept. 30, 2021: € 3,014 k). An amount of € 10 k was added to pension provisions. Other provisions decreased to € 1,691 k, partly due to lower personnel provisions. Liabilities decreased by € 1,296 k to € 3,666 k (September 30, 2021: € 4,962 k), mainly due to the reduction in liabilities to shareholders at the balance sheet date. Deferred income increased by € 165 k to € 1,567 k due to higher customer prepayments for services to be rendered by the Company in the future compared to the previous year.

The Company's cash and cash equivalents (cash on hand, bank balances) decreased from € 7,621 k to € 4,309 k in the first half of the year.

Overall, the net assets, financial position and results of operations developed very satisfactorily.

OPPORTUNITIES AND RISK REPORT

Since the beginning of the financial year, there have been no significant changes with regard to the risk situation of the Company. The disclosures made in the report on opportunities and risks in the financial statements as of the end of the financial year ended September 30, 2021 therefore continue to apply.

OUTLOOK

At this point in time, we are confirming our forecast: For the financial year 2021/2022, revenues are now expected to remain stable compared with the previous year at between € 16.0 million and € 16.5 million. In addition to the slight decline in sales with the customer Hologic, slightly increasing sales revenues are expected in the area of development services. For earnings before interest and taxes (EBIT), we also expect stability in the range of € 4.0 million to € 4.5 million. The forecast sales stability, with an expected balanced result from exchange rate differences, is the main driver for the unchanged outlook for EBIT. Possible effects of the current Corona pandemic have played a role in the budget preparation. It is very difficult to assess possible impacts. On the one hand, we know that service providers (e.g. hospitals) are making fewer resources available for investments due to other priorities at present, but on the other hand we have not been able to identify any significant decline in our business in the last 12 months as a result of the Corona pandemic and have therefore not made any specific Corona deductions from our budget.

As in the previous reporting period, the Executive Board will regularly review its expectations in the further course of fiscal 2021/2022 on the basis of current business developments.

Bremen, May 30, 2022



Marcus Kirchhoff

CEO

BALANCE SHEET

of MeVis Medical Solutions AG, Bremen, as of March 31, 2022

ASSETS (FIGURES IN €)	Mar. 31, 2022	Sept. 30, 2021
A. Fixed Assets		
I. Intangible assets		
Concessions, patents, licenses, trade marks and similar rights and assets	246.87	338.46
II. Tangible assets		
Property, plant and equipment	115,508.28	121,792.75
III. Financial assets		
1. Shares in affiliated companies	312,042.00	312,042.00
2. Loans to affiliated companies	16,225,211.69	16,225,211.69
	16,537,253.69	16,537,253.69
	16,653,008.84	16,659,384.90
B. Current Assets		
I. Receivables and other assets		
1. Trade receivables	3,387,378.68	2,271,865.82
2. Receivables from affiliated companies	781,783.47	526,847.70
3. Other assets	277,122.50	354,254.52
	4,446,284.65	3,152,968.04
II. Cash in hand, credit balances with credit institutions		
	4,309,210.98	7,621,040.17
	8,755,495.63	10,774,008.21
C. Deferred income	105,105.32	100,202.83
	25,513,609.79	27,533,595.94

EQUITY AND LIABILITIES (FIGURES IN €)	Mar. 31, 2022	Sept. 30, 2021
A. Equity		
I. Subscribed capital		
Subscribed capital	1,820,000.00	1,820,000.00
II. Capital reserve	11,461,332.48	11,461,332.48
III. Revenue reserve		
1. Legal reserve	5,000.00	5,000.00
2. Other revenue reserve	4,539,688.30	4,539,688.30
	4,544,688.30	4,544,688.30
	17,826,020.78	17,826,020.78
B. Accruals/Provisions		
1. Accruals for pensions	494,449.50	483,608.00
2. Tax accruals	268,576.03	254,344.75
3. Other accruals	1,690,917.22	2,275,765.09
	2,453,942.75	3,013,717.84
C. Liabilities		
1. Payments received on account of orders	10,134.39	26,848.87
2. Trade payables	83,449.38	239,758.66
3. Payable to affiliated companies	3,420,815.11	4,545,681.16
4. Other liabilities	151,850.20	149,253.52
	3,666,249.08	4,961,542.21
D. Deferred income	1,567,397.18	1,732,315.11
	25,513,609.79	27,533,595.94

PROFIT AND LOSS ACCOUNT

of MeVis Medical Solutions AG, Bremen, for the period October 1, 2021 through March 31, 2022

FIGURES IN €	2021/2022	2020/2021
1. Revenues	8,545,962.40	8,080,155.93
2. Other operating income	1,030,771.90	781,247.61
3. Cost of material		
a) Cost of purchased goods	33,283.75	0,00
b) Cost of purchased services	160,403.32	97,947.83
	193,687.07	97,947.83
4. Staff cost		
a) Wages and salaries	3,642,866.96	3,663,673.42
b) Social security and pension expenses	725,658.15	687,150.62
	4,368,525.11	4,350,824.04
5. Depreciation and amortization on intangible fixed assets and tangible assets	49,777.62	63,818.86
6. Other operating expenses	1,586,045.81	1,970,483.15
7. Other interest and similar income	84,616.42	79,873.96
8. Interest and similar expenses	0.00	54.00
9. Taxes on income	42,500.00	42,500.00
10. Net income after tax	3,420,815.11	2,415,649.62
11. Profit to be transferred on the basis of a profit transfer agreement	3,420,815.11	2,415,649.62
12. Net income / net loss	0.00	0.00

NOTES TO THE FINANCIAL STATEMENTS

of the half-year financial report of MeVis Medical Solutions AG, Bremen,
as of March 31, 2022

BASIC INFORMATION

GENERAL INFORMATION

The registered office of the Company is in Bremen, Germany. The Company address is: Caroline-Herschel-Strasse 1, 28359 Bremen, Germany. MMS AG is entered in the Commercial Register at Bremen Local Court (HRB 23791 HB).

73.66 % of the share capital of MMS AG is currently held by Varex Imaging Deutschland AG, Willich. There is a domination and profit and loss transfer agreement between Varex Imaging Deutschland AG as the controlling company and MeVis Medical Solutions AG as the controlled company. As a result, MMS AG belongs to the Varex Group via Varex Imaging Deutschland AG under the management of Varex Imaging Corporation, Salt Lake City, Utah, USA.

MeVis Medical Solutions AG has prepared its annual financial statements for financial year 2020/2021 in accordance with the provisions of the German Commercial Code (HGB) applicable to corporations and the German Stock Corporation Act (AktG). These interim financial statements have also been prepared on this basis. These interim financial statements were neither reviewed nor audited in accordance with Section 317 of the German Commercial Code.

ACCOUNTING AND VALUATION METHODS

In preparing the interim financial statements and determining the comparative figures for the previous year, the same accounting policies were applied as in the 2020/2021 annual financial statements. A detailed description of these methods is published in the notes to the annual financial statements 2020/2021.

SELECTED NOTES ON THE BALANCE SHEET AND INCOME STATEMENT

1. RECEIVABLES AND OTHER ASSETS

All receivables have a remaining term of up to one year.

Trade receivables amounted to € 3,387 k (Sept. 30, 2021: € 2,272 k) as of the balance sheet date and relate primarily to receivables from the customers Hologic, Vital Images and Invivo.

Receivables from affiliated companies include € 113 k (Sept. 30, 2021: € 64 k) in trade receivables from MBC KG and € 584 k (Sept. 30, 2021: 463 k) in trade receivables from Varex Imaging Deutschland AG and Varex Imaging Corporation. In addition, receivables from affiliated companies include short-term interest receivables of € 85 k (Sept. 30, 2021: € 0 k) from a loan granted to Varex Imaging Deutschland AG.

Other assets amounted to € 277 k (Sept. 30, 2021: € 354 k) as of the balance sheet date. These mainly relate to a rent deposit of € 250 k and receivables from a grant project.

2. ACCRUALS/PROVISIONS

Other provisions amount to € 1,691 k (Sept. 30, 2021: € 2,276 k). Of these, € 452 k (Sept. 30, 2021: € 459 k) mainly relate to the defense of a patent lawsuit, € 287 k (Sept. 30, 2021: € 265 k) to provisions for vacation and overtime, € 286 k (Sept. 30, 2021: € 355 k) relate to outstanding invoices, € 255 k (Sept. 30, 2021: € 574 k) to provisions for bonuses, € 175 k (Sept. 30, 2021: € 385 k) to provisions for the 13th salary and € 151 k (Sept. 30, 2021: € 151 k) to provisions for guarantees.

3. LIABILITIES

In the reporting period, trade payables decreased by € 17 k and amounted to € 10 k at the balance sheet date. Liabilities to affiliated companies of € 3,421 k (Sept. 30, 2021: € 4,546 k) relate to the profit transfer under the existing control and profit transfer agreement with Varex Imaging Deutschland AG. The liability will legally only arise at the end of financial year 2021/2022.

4. DEFERRED INCOME

This item includes deferred revenue components from multi-component contracts that have already been paid but not realized. In addition, payments received from maintenance contracts are deferred if the corresponding maintenance service has not yet been performed.

5. REVENUES

The revenues are divided into the following revenue types:

FIGURES IN € k	Oct. 1, 2021 - Mar. 31, 2022	Oct. 1, 2020 - Mar. 31, 2021
Services (consulting and training)	3,740	2,819
Maintenance (software service contracts)	2,615	2,862
Software and licenses	2,191	2,399
	8,546	8,080

6. OTHER OPERATING INCOME

Other operating income in the first half-year amounted to € 1,031 k (prev. year: € 718 k). Of this amount, € 955 k (prev. year: € 660 k) is mainly attributable to exchange rate differences. The exchange rate differences are due to the fact that the majority of services are invoiced in US dollars and that liquidity is also held in US dollars. Due to the fact that the Company belongs to the Varex Imaging Group and in line with its corporate policy, no exchange rate hedging transactions are concluded.

7. STAFF COSTS

The average number of employees was 104 (prev. year: 104). This corresponds to an average of 95 full-time equivalents (prev. year: 95).

8. OTHER OPERATING EXPENSES

Other operating expenses in the first half of the year amounted to € 1,586 k (prev. year: € 1,970 k). These are mainly attributable to expenses from exchange rate differences of € 629 k (prev. year: € 724 k), rental expenses of € 238 k (prev. year: € 267 k) and legal, consulting and auditing costs of € 216 k (prev. year: € 443 k), sales expenses of € 63 k (prev. year: € 21 k), operating expenses of € 56 k (prev. year: € 54 k) and other operating expenses of € 384 k (prev. year: € 460 k).

9. RELATIONSHIPS WITH RELATED PARTIES

The Company carries out transactions with related parties, which are explained below. These are part of the ordinary business activity and are handled as if they were with third parties.

Related parties include the jointly managed companies MBC KG and MBC GmbH, Varex Imaging Deutschland AG and, through these companies, the affiliated companies of the Varex Group, as well as the Executive Board and the Supervisory Board and their close relatives.

The following receivables, liabilities, expenses and income of the Company relate to related parties:

FIGURES IN € K	2021/2022
Parent company	
Receivables (from granting of loans)	16,310
Receivables (from services)	77
Liabilities (from profit transfer agreement)	3,420
Income (mainly services and interest income)	476
Expenses (from profit transfer agreement)	3,420
Other affiliated companies	
Receivables (from services)	619
Income (mainly services and interest income)	1,463

MATERIAL EVENTS OCCURRING AFTER THE BALANCE SHEET DATE

There were no business transactions of particular significance for the Company after the balance sheet date.

ASSURANCE OF THE LEGAL REPRESENTATIVE

"To the best of my knowledge, and in accordance with the applicable reporting principles for half-yearly financial reporting, the interim financial statements of MeVis Medical Solutions AG give a true and fair view of the assets, liabilities, financial position and profit or loss of the MeVis Medical Solutions AG and the interim management report includes a fair review of the development and performance of the business and the position of MeVis Medical Solutions AG, together with a description of the principal opportunities and risks associated with the expected development of MeVis Medical Solutions AG for the remaining months of the financial year."

Bremen, May 30, 2022

MeVis Medical Solutions AG

A handwritten signature in black ink, appearing to read 'Marcus Kirchhoff', with a stylized flourish at the end.

Marcus Kirchhoff

CEO

DISCLAIMER

FORWARD-LOOKING STATEMENT

This report contains forward-looking statements which are based on management's current estimates of future developments. Such statements are subject to risks and uncertainties, which MeVis Medical Solutions AG is not able to control or estimate with any precision, e.g. future market conditions and the general economic environment, the behavior of other market participants, the successful integration of new acquisitions and government acts. If any of these uncertainties or imponderabilities materialize or if the assumptions on which these statements are based prove to be incorrect, this may cause actual results to deviate materially from those expressly or implicitly contained in these statements. MeVis Medical Solutions AG does not intend and is under no obligation to update the forward-looking statements in the light of any events or developments occurring after the date of this report.

DEVIATIONS FOR TECHNICAL REASONS

Deviations may occur between the accounting data contained in this report and that submitted to the Bundesanzeiger for technical reasons (e.g. conversion of electronic formats). In the case of any doubt, the version submitted to the Bundesanzeiger will prevail.

This report is also available in a German-language version. In case of any doubt, the German-language version takes priority over the English-language one.

The report is available for downloading in the internet at:
<http://www.mevis.de/en/investor-relations/financial-reports/>

MeVis Medical Solutions AG

Caroline-Herschel-Str. 1
28359 Bremen
Germany

Phone +49 421 22495 0
Fax +49 421 22495 999
info@mevis.de

www.mevis.de